Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Clin Infect Dis. 2022 Sep 14;75(5):768-776. doi: 10.1093/cid/ciab1067.
Evidence describing the impact of diabetes mellitus (DM) on the recurrence and mutation rate of Mycobacterium tuberculosis (Mtb) is limited.
This study was nested in 3 cohort studies of tuberculosis (TB) patients with and without DM in India. Paired Mtb isolates recovered at baseline and treatment failure/recurrence underwent whole genome sequencing. We compared acquisition of single-nucleotide polymorphisms (SNPs), TB drug resistance mutations, and type of recurrence (endogenous reactivation [<8 SNPs] or exogenous reinfection [≥8 SNPs]) by DM status.
Of 1633 enrolled in the 3 parent cohorts, 236 (14.5%) had microbiologically confirmed TB treatment failure/recurrence; 76 Mtb isolate pairs were available for sequencing (22 in TB-DM and 54 in TB-only). The SNP acquisition rate was overall was 0.43 (95% confidence interval [CI], .25-.64) per 1 person-year (PY); 0.77 (95% CI, .40-1.35) per 1 PY, and 0.44 (95% CI, .19-.86) per 1 PY at treatment failure and recurrence, respectively. Significant difference in SNP rates by DM status was seen at recurrence (0.21 [95% CI, .04-.61]) per 1 PY for TB-only vs 1.28 (95% CI, .41-2.98) per 1 PY for TB-DM; P = .02). No significant difference in SNP rates by DM status was observed at treatment failure. Acquired TB drug resistance was seen in 4 of 18 (22%) in TB-DM vs 4 of 45 (9%) in TB-only (P = .21). Thirteen (17%) participants had exogenous reinfection; the reinfection rate at recurrence was 25% (3/12) for TB-DM vs 17% (4/24) in TB-only (P = .66).
Considerable intrahost Mtb mutation rates were present at recurrence among patients with DM in India. One-fourth of patients with DM had exogenous reinfection at recurrence.
有关糖尿病(DM)对结核分枝杆菌(Mtb)复发和突变率影响的证据有限。
本研究嵌套在印度三项糖尿病合并和不合并结核病(TB)患者的队列研究中。在基线和治疗失败/复发时采集配对的 Mtb 分离株进行全基因组测序。我们比较了 DM 状态下单核苷酸多态性(SNP)、TB 耐药突变和复发类型(<8 个 SNP 的内源性再激活或≥8 个 SNP 的外源性再感染)的获得情况。
在 3 项主要队列研究中,共纳入了 1633 名患者,其中 236 名(14.5%)经微生物学证实存在 TB 治疗失败/复发;有 76 对 Mtb 分离株可供测序(TB-DM 组 22 对,TB 组 54 对)。总的 SNP 获得率为 0.43(95%可信区间 [CI],0.25-0.64)/人年;治疗失败和复发时分别为 0.77(95%CI,0.40-1.35)/人年和 0.44(95%CI,0.19-0.86)/人年。TB 组和 TB-DM 组复发时 SNP 率的差异有统计学意义(TB 组为 0.21 [95%CI,0.04-0.61]/人年,TB-DM 组为 1.28 [95%CI,0.41-2.98]/人年;P=0.02),但在治疗失败时差异无统计学意义。TB-DM 组有 4 例(22%)获得了 TB 耐药,TB 组有 4 例(9%)获得了耐药(P=0.21)。13 例(17%)患者发生了外源性再感染;TB-DM 组的再感染率为 25%(3/12),TB 组为 17%(4/24)(P=0.66)。
在印度,DM 患者的 Mtb 体内突变率在复发时相当高。四分之一的 DM 患者在复发时发生了外源性再感染。